Skin cancer

SciBase capital markets day 2024 - save the date

Retrieved on: 
Thursday, December 28, 2023
Skin, Skin cancer, Digital, Karolinska Institute, SCIB, Pinnacle, Physician

STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase's way forward, updated strategy and long-term goals.
  • The presentations will focus on the USA as well as SciBase's ongoing establishment in new promising markets.
  • Pinnacle, an independent specialist company in the US reimbursement system, will explain the SciBase path towards reimbursement in the US.

Schweiger Dermatology Group Expands into South Florida with Locations in West Palm Beach and Miami Beach

Retrieved on: 
Thursday, December 21, 2023
Priyanka Shah, Growth, Skin cancer, Patient, DRS, MIAMI, Dermatology, PALM, Risk

WEST PALM BEACH, Fla. and MIAMI BEACH, Fla., Dec. 21, 2023 /PRNewswire/ -- Schweiger Dermatology Group, the leading dermatology practice on the East Coast, has opened a new office in West Palm Beach with another location opening in Miami Beach in early 2024.

Key Points: 
  • WEST PALM BEACH, Fla. and MIAMI BEACH, Fla., Dec. 21, 2023 /PRNewswire/ -- Schweiger Dermatology Group, the leading dermatology practice on the East Coast, has opened a new office in West Palm Beach with another location opening in Miami Beach in early 2024.
  • Schweiger Dermatology Group acquired a dermatology practice in Leesburg in July 2023, marking its entrance into Florida.
  • "This is a very exciting time for us as we expand into South Florida," says Dr. Eric Schweiger, founder, and C.E.O.
  • The new Schweiger Dermatology Group South Florida offices are:

Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board

Retrieved on: 
Tuesday, December 19, 2023
Associate, Human voice, GSA, ACMS, FDA, Syndrome, SAB, Skin cancer, AAD, Cancer, Mohs surgery, Diagnosis, Treasurer, Genetic distance, Neck, Cancer syndrome, Drug development, Trial of the century, Medicine, Literature, American Academy, University, Safety, Patient, Neoplasm, Therapy, Frederic E. Mohs, OTCQB, Toxicity, Scar, Inhibitor, Glomus tumor, Education, Faculty, Cleveland Clinic, RECIST, Research, System, Patient safety, Nevoid basal-cell carcinoma syndrome, Yale University, Cornell University, Oncology, NDA, INTI, American College, Face, Carcinoma, Organization, Skin, Pharmaceutical industry

TAMPA, Fla., Dec. 19, 2023 /PRNewswire/ -- At the forefront of the Inhibitor Therapeutics, Inc. (OTCQB:INTI) pipeline is the use of Itraconazole to treat basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome (BCCNS) aka Gorlin Syndrome. This rare hereditary cancer syndrome is characterized by patients with hundreds to thousands of basal cell carcinomas. BCCNS is an orphan disease with approximately 11,000 patients in the USA. It is an autosomal dominant disorder that may affect every organ system. 

Key Points: 
  • Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons to form a Scientific Advisory Board (SAB) to critically review the outcomes of Inhibitor's phase 2b trial in BCCNS.
  • She is affiliated with the Gorlin Syndrome Alliance and is a member of their Medical and Scientific Advisory Committee.
  • She was a member of the Scientific Assembly Committee and Membership Committee for the American Academy of Dermatology (AAD) 2012-17.
  • She was appointed to the Board of Directors for the American Board of Dermatology for 2019-2027 and is a member and Chairman of the board question writing committee for dermatologic surgery.

U.S. Dermatology Partners Opens Dedicated Mohs and Facial Plastic Surgery Center in Peoria, Arizona

Retrieved on: 
Tuesday, December 19, 2023
Suite, Patient, Sonoran Desert, Lake Pleasant Regional Park, Workflow, Skin cancer, Seattle Mariners, Mohs surgery, Dermatology, San Diego Padres, Camping, Dentistry

PEORIA, Ariz., Dec. 19, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its Mohs and Facial Plastic Surgery Center in Peoria, Arizona on December 18th, 2023. This new office will focus primarily on treatment for skin cancer cases that require surgical and reconstructive care. The state-of-the-art office includes 4000 square feet of space, including eight surgical rooms and a dedicated waiting area. The office is staffed by fellowship-trained Mohs surgeons Drs. Deborah Zell, James Foshee, and Iviensan Manalo, as well as Dr. Sam DeVictor, a facial plastic surgeon who specializes in facial plastic surgery and Mohs reconstruction. Patients will benefit from a more efficient workflow, especially for patients with complex or large skin cancers requiring the coordination of a plastic surgeon for closure.

Key Points: 
  • U.S. Dermatology Partners expands access to skin cancer treatment and cosmetic surgery to patients in Maricopa County with the opening of the organization's newest Mohs and facial plastic surgery center.
  • PEORIA, Ariz., Dec. 19, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its Mohs and Facial Plastic Surgery Center in Peoria, Arizona on December 18th, 2023.
  • Deborah Zell , James Foshee , and Iviensan Manalo , as well as Dr. Sam DeVictor , a facial plastic surgeon who specializes in facial plastic surgery and Mohs reconstruction.
  • "We are pleased to make Mohs surgery and reconstruction more accessible and convenient to skin cancer patients in Maricopa County," said Paul Singh, Chief Executive Officer of U.S. Dermatology Partners.

FDA Breakthrough Device using Optical Spectroscopy was Found to Significantly Increase Physicians’ Detection of Skin Cancer

Retrieved on: 
Wednesday, December 13, 2023
Other Health, Pharmaceutical, Research, Other Technology, Oncology, Software, Medical Devices, Hardware, Hospitals, Science, Practice Management, Technology, Nursing, Clinical Trials, Managed Care, FDA, Alternative Medicine, Surgery, Health, Sale, Skin, Skin cancer, ESS, Risk, American Academy, Patient, Journal, Machine learning, PCP, University, MD, Trial of the century, Diagnosis, Cancer, Community health, Physician, Medical imaging, Dermatology

This study, authored by medical leaders including Laura Korb Ferris, MD, and Todd Thames, MD, evaluated the impact of the DermaSensor device on PCPs’ skin cancer diagnosis and management.

Key Points: 
  • This study, authored by medical leaders including Laura Korb Ferris, MD, and Todd Thames, MD, evaluated the impact of the DermaSensor device on PCPs’ skin cancer diagnosis and management.
  • The device, which employs elastic scattering spectroscopy (ESS) and machine learning, was found in this utility study to significantly improve PCPs’ referral of malignant lesions to dermatologists.
  • The device has been under review by the FDA since early 2023; it is not currently available for sale in the United States.
  • Skin cancer remains the most prevalent type of cancer in the United States, posing a significant challenge for PCPs who often encounter patients with suspicious skin lesions.

New Study of an AI-Powered Spectroscopy Device Shows Promise for Skin Cancer Detection

Retrieved on: 
Tuesday, November 21, 2023
Oncology, General Health, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Other Health, Carcinoma, Sale, Malignancy, Skin cancer, Safety, Hope, Incidence, AUC, ESS, Dermatology, Artificial intelligence, NNB, Data, Patient, Multimedia, FDA, PCP, PPV, Melanoma, NPV, Skin, Overalls, Biopsy, Medical imaging

A newly published study was designed to evaluate the safety and effectiveness of an Elastic Scattering Spectroscopy (ESS) device, the DermaSensor device, in assessing skin lesions suggestive of skin cancer.

Key Points: 
  • A newly published study was designed to evaluate the safety and effectiveness of an Elastic Scattering Spectroscopy (ESS) device, the DermaSensor device, in assessing skin lesions suggestive of skin cancer.
  • These lesions underwent clinical evaluation by expert dermatologists and by the DermaSensor device, a handheld AI-powered spectroscopy device that is non-invasive and wireless.
  • This innovation holds the promise of improving skin cancer care by facilitating expedited and improved detection and intervention.
  • “This study was a key early comparative effectiveness study showing that our device can bring dermatologist-level triage to primary care.

DMTK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Tuesday, November 21, 2023
Class Action Lawsuit, Professional Services, Legal, Skin cancer, Collection, CASE, ASP, Melanoma, Diagnosis, Growth, News, Tobacco

If you suffered substantial losses and wish to serve as lead plaintiff of the DermTech class action lawsuit, please provide your information here:

Key Points: 
  • If you suffered substantial losses and wish to serve as lead plaintiff of the DermTech class action lawsuit, please provide your information here:
    You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] .
  • A lead plaintiff acts on behalf of all other class members in directing the DermTech class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the DermTech class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the DermTech class action lawsuit.

Orphan designation: Dabrafenib mesylate Treatment of glioma, 09/12/2020 Positive

Retrieved on: 
Monday, December 18, 2023
Glioma, Vomiting, Medicine, Eurostat, COMP, Skin cancer, Pressure, Brain, Safety, Radiation, Merrion Road, European Commission, Ageing, Disease, Headache, Civil service commission, Patient, European, Skull, Dabrafenib, Marketing, Lung cancer, Muscle weakness, Committee, Seizure, Melanoma, BRAF, Population, Nausea, Survival, Cancer, Diagnosis, Date rape drug, Growth, Regulation, Personality, EURORDIS, Knowledge, Tribhuvan University, Cell, Pharmaceutical industry, Medical device, Medical imaging, Vaccine

Orphan designation: Dabrafenib mesylate Treatment of glioma, 09/12/2020 Positive

Key Points: 


Orphan designation: Dabrafenib mesylate Treatment of glioma, 09/12/2020 Positive

Inner Glow's Sol Defense Gummies Made to Help Protect Consumers from UV Rays

Retrieved on: 
Tuesday, December 12, 2023
Skin cancer, Perspiration, Research, Tannin, Amazon, CNN, Smash Mouth, Dermatology, Collection, Patient, UV, FDA, Rejuvenation, Polypodium, Ageing, Water, Plastic, Physician, Inner Glow, Plastic surgery, Birth control, Cosmetics, Nicotinamide

CHANTILLY, Va., Dec. 12, 2023 /PRNewswire/ -- The world is getting hotter and CEO and founder of Inner Glow, Dr. Galaria says this doesn't just impact our surroundings, it also impacts us as people because UV levels and temperatures are correlated. As physicians who diagnose and treat skin cancer it's critical we educate the public about the importance of sunscreen and additional sun protection methods. According to CNN, "two major reports published last month paint an alarming picture of this unprecedented heat: Humanity has just lived through the hottest 12-month period in at least 125,000 years, according to one, while the other declared that 2023 is "virtually certain" to be the hottest year in recorded history, after five consecutive months of record-obliterating temperatures."

Key Points: 
  • Our Dermatologist and Plastic Surgeon developed brand Inner Glow has two products to help protect against sun damage, Sol Defense and Age Defense ($29.99 & $48.00 at innerglowvitamins.com and amazon.com ).
  • Sol Defense is an easy and delicious, on-the-go gummy that can be taken anywhere without water or the need to swallow large pills.
  • Easily throw Sol Defense into a beach bag, as it will maintain its shape and not melt at even 170+ degrees, unlike other gelatin-based gummies.
  • Dr. Noreen Galaria, Board certified Dermatologist and Founder of Inner Glow vitamins says, "layering sun protection is important.

Renowned Miami-Based Facial Plastic Surgeon, Dr. Anthony Bared Earns Over 300 Google Reviews

Retrieved on: 
Tuesday, December 12, 2023
Deformity, Nose, Skin cancer, Cartilage, Rhinoplasty, Patient, Injury, Substance abuse, Face, Accident, Dentistry, Medical device, MIAMI

MIAMI, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Celebrating a Milestone: Over 300 Positive Google Reviews for Dr. Anthony Bared

Key Points: 
  • Renowned Miami-based facial plastic surgeon, Dr. Anthony Bared, has reached a significant milestone in patient satisfaction, earning over 300 positive Google reviews.
  • This achievement is a testament to his expertise, patient-centered approach, and commitment to excellence in the field of facial plastic surgery.
  • MIAMI, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Celebrating a Milestone: Over 300 Positive Google Reviews for Dr. Anthony Bared
    In an era where online reputation significantly influences patient choice, Dr. Anthony Bared has proven to be a trusted name in facial plastic surgery.
  • Garnering over 300 positive Google reviews , his Miami practice has become an esteemed destination for patients seeking high-quality surgical and non-surgical treatments.